The US biotech claims an unexpected victory, scoring a $2.1bn takeover by Novartis on the strength of an asset it had bought for just $12m.
Sage Therapeutics will report the first pivotal data with its oral postpartum depression candidate, while Biohaven Pharma transfers its hopes to a faster-acting migraine…
As Anaptysbio pushes forward with its new biological, the cost watchdog Icer questions the prices of products from Glaxosmithkline, Astrazeneca and Teva.
Competition in the CGRP migraine space has left both Teva and Amgen willing to take hits on sales to hook new patients.
A non-profit partnership of 500 hospitals wants to deliver its first generic drugs in 2019, lowering prices and stabilising supplies.
Chi-Med is not alone in seeing Chinese approval as the prelude to a regulatory green light in the west.
September promises at least eight notable US marketing decisions, including a crucial lung cancer ruling for Roche’s Tecentriq and verdicts on Lilly and Teva’s competing…
Biohaven might soon be going up against Allergan in the acute migraine space, but the company believes size will not be a barrier to its success.